Rocket Pharmaceuticals, Inc.
- Open
- 3.77
- Day high
- 3.80
- Day low
- 3.64
- Prev close
- 3.86
- Volume
- 1.6M
- Mkt cap
- $408M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 1.1
- P/S
- —
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$176K over the last 3 months (0 open-market buys, 6 sales)
- 🏛Institutions accumulating (13F)
Rocket Pharmaceuticals, Inc. (RCKT) is a Healthcare company listed on NASDAQ. The stock is up 15% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 6 sales (SEC Form 4).
Rocket Pharmaceuticals, Inc. (RCKT) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
RCKT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 10, 2026 | $0.86 | $1.08 | +25.6% | — | — |
| May 7, 2026 | $-0.41 | $-0.42 | -2.4% | — | — |
| Nov 6, 2025 | $-0.48 | $-0.45 | +6.2% | — | — |
| Aug 7, 2025 | $-0.57 | $-0.59 | -3.5% | — | — |
| May 8, 2025 | $-0.59 | $-0.56 | +5.1% | — | — |
| Feb 27, 2025 | $-0.68 | $-0.62 | +8.8% | — | — |
| Nov 7, 2024 | $-0.78 | $-0.71 | +9.0% | — | — |
| Feb 26, 2024 | $-0.80 | $-0.64 | +20.0% | $10M | — |
| Aug 10, 2023 | $-0.80 | $-0.82 | -2.5% | — | — |
| May 4, 2023 | $-0.86 | $-0.73 | +15.1% | — | — |
| Feb 27, 2023 | $-0.81 | $-0.92 | -13.6% | — | — |
| Nov 3, 2022 | $-0.77 | $-0.87 | -13.0% | — | — |
RCKT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 20, 2026 | Wilson Martinofficer: General Counsel | Sell | 631 | $3.38 |
| Aug 20, 2026 | Shah Gauravofficer: CEO | Sell | 2,293 | $3.38 |
| Aug 17, 2026 | Shah Gauravofficer: CEO | Sell | 2,837 | $3.38 |
| Aug 17, 2026 | Wilson Martinofficer: General Counsel | Sell | 3,493 | $3.38 |
| Aug 13, 2026 | Chaudhuri Sarbaniofficer: See Remarks | Sell | 4,701 | $3.50 |
| Aug 13, 2026 | Stevens Christopher Jamesofficer: Chief Operating Officer | Sell | 36,658 | $3.50 |
| Aug 5, 2026 | Stevens Christopher Jamesofficer: Chief Operating Officer | Grant | 101,428 | $3.41 |
| Aug 5, 2026 | Stevens Christopher Jamesofficer: Chief Operating Officer | Grant | 73,313 | — |
| Jul 6, 2026 | SOUTHWELL DAVID Pdirector | Grant | 22,862 | — |
| Jul 6, 2026 | Malik Fady Ibrahamdirector | Grant | 64,860 | $3.35 |
| Jul 6, 2026 | Malik Fady Ibrahamdirector | Grant | 22,862 | — |
| Jul 6, 2026 | Dolsten Mikaeldirector | Grant | 22,862 | — |
| Jul 6, 2026 | BOESS CARSTENdirector | Grant | 22,862 | — |
| Jul 6, 2026 | Fong Peterdirector | Grant | 22,862 | — |
| Jul 6, 2026 | WONG RODERICKdirector, 10 percent owner: | Grant | 78,960 | $3.35 |
Source: RCKT SEC Form 4 filings, latest Aug 20, 2026. For informational purposes only — not investment advice.
See the full RCKT insider & 13F page →Rocket Pharmaceuticals, Inc. company profile
Overview
Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a clinical-stage biotechnology company founded in 2015 and headquartered in Cranbury, New Jersey. The company specializes in developing gene therapies for rare and devastating genetic diseases, operating as a multi-platform biotechnology enterprise with both ex vivo and in vivo gene therapy programs. Since its initial public offering in February 2015, Rocket has focused exclusively on advancing innovative treatments for patients with limited therapeutic options, particularly those suffering from rare genetic disorders affecting blood cells, immune function, and organ systems.
Business
Rocket Pharmaceuticals operates in the gene therapy sector of biotechnology, which represents one of the most cutting-edge areas of modern medicine. Gene therapy involves introducing genetic material into a patient's cells to treat or prevent disease, essentially correcting defective genes or providing new cellular functions. This approach is particularly promising for rare genetic diseases where traditional pharmaceutical interventions have proven inadequate. The company's pipeline consists of two distinct technological platforms. Ex vivo lentiviral vector programs represent the majority of Rocket's clinical portfolio, involving the removal of a patient's cells, genetic modification in the laboratory using lentiviral vectors (modified viruses that can safely deliver therapeutic genes), and reinfusion of the corrected cells back into the patient. This approach is being pursued for three rare diseases: Fanconi Anemia, a bone marrow disorder that impairs blood cell production; Leukocyte Adhesion Deficiency-I (LAD-I), an immune system disorder that prevents white blood cells from fighting infections effectively; and Pyruvate Kinase Deficiency, a red blood cell disorder causing chronic anemia. The company's in vivo adeno-associated virus (AAV) program takes a different approach, delivering therapeutic genes directly to patients through injection of modified AAV vectors. This platform is being developed for Danon Disease, a rare genetic disorder affecting multiple organs, particularly the heart, and typically leading to heart failure and early death. The in vivo approach eliminates the need for cell extraction and laboratory manipulation, potentially offering a more straightforward treatment administration. These programs collectively address ultra-rare diseases affecting small patient populations, typically numbering in the hundreds to low thousands globally. The company's focus on rare diseases reflects both the significant unmet medical need in these conditions and the regulatory advantages available through orphan drug designations, which provide extended market exclusivity and streamlined approval pathways.
Competitive moat
Rocket Pharmaceuticals operates in a highly specialized field with limited direct competition, but its competitive moat remains relatively narrow and largely dependent on execution excellence rather than fundamental structural advantages. The company's primary defensive positions stem from its specialized expertise in rare disease gene therapy and established relationships with key research institutions through licensing agreements with prestigious organizations including Fred Hutchinson Cancer Research Center and The Regents of the University of California. The most significant moat element lies in regulatory exclusivity through orphan drug designations, which provide seven years of market exclusivity upon approval in the United States and ten years in Europe. This regulatory protection is substantial for rare diseases, as the small patient populations make competitive entry economically challenging even after exclusivity expires. Additionally, the company's clinical trial data and regulatory relationships represent valuable assets that would be difficult for competitors to replicate quickly. However, Rocket's moat faces considerable vulnerabilities. The gene therapy field attracts substantial competition from well-funded biotechnology companies, large pharmaceutical corporations, and academic medical centers, many with superior financial resources and broader platform capabilities. Companies like bluebird bio, Orchard Therapeutics, and various programs within major pharmaceutical companies pursue similar approaches for overlapping rare diseases. The underlying technologies, while sophisticated, are not proprietary to Rocket, and lentiviral and AAV vector platforms are widely accessible. The company's competitive position is primarily temporal rather than structural - success depends on reaching market first with effective treatments rather than controlling unique, defensible technology. Manufacturing capabilities for gene therapy remain specialized but are increasingly available through contract manufacturing organizations, reducing this potential barrier to entry. Furthermore, the company's dependence on licensed technologies from external partners limits its control over core intellectual property. Most critically, Rocket's moat remains theoretical until clinical success is demonstrated. The binary nature of drug development means that clinical failures could eliminate competitive advantages entirely, while successful competitors could establish superior positions through better clinical results, faster development timelines, or more favorable safety profiles. The company's competitive strength ultimately rests on execution excellence in an inherently risky and uncertain development process.
Risks & safety
Rocket Pharmaceuticals presents a mixed margin of safety profile typical of clinical-stage biotechnology companies, with strong balance sheet liquidity offset by significant cash burn and binary execution risks. • Liquidity position: Strong current ratio of 9.2x with $163.6 million in cash and short-term investments as of Q4 2024, providing substantial near-term financial flexibility • Cash burn analysis: Operating cash flow burn of approximately $210 million annually (2024), suggesting current cash provides roughly 9-12 months of runway at current spending levels, creating moderate near-term funding pressure • Debt burden: Minimal debt with debt-to-equity ratio of only 0.055, indicating very low financial leverage and solvency risk • Valuation metrics: Trading at 2.6x book value with negative earnings making traditional valuation metrics less meaningful; enterprise value reflects significant premium to tangible assets • Operational risks: Zero revenue generation with $259 million net loss in 2024, creating complete dependence on capital markets for funding and clinical program success for value realization • Binary development risk: Clinical-stage programs face substantial execution risk with potential for complete value destruction upon clinical failures, while regulatory and commercial uncertainties add additional layers of risk to any investment thesis
Recent development
Based on the available financial data, Rocket Pharmaceuticals has maintained consistent focus on advancing its gene therapy pipeline over recent years, though specific strategic developments are limited due to the absence of detailed earnings call transcripts. The company's financial trajectory shows sustained investment in research and development with annual operating losses remaining relatively stable between $210-260 million from 2022 through 2024, indicating continued commitment to clinical program advancement. The company's balance sheet management demonstrates strategic capital allocation with periodic equity raises maintaining cash reserves, evidenced by cash positions fluctuating between $38 million and $164 million across recent quarters. This pattern suggests ongoing efforts to balance clinical investment with financial runway optimization. The maintenance of minimal debt levels throughout this period indicates management's preference for equity financing over debt instruments, typical for clinical-stage biotechnology companies. Recent financial performance shows increasing operational efficiency in some areas, with quarterly cash burn showing some variability but generally remaining within expected ranges for a company with multiple active clinical programs. The company's asset base has remained relatively stable, suggesting focused investment in core program development rather than significant expansion into new therapeutic areas or major infrastructure investments. Without specific earnings call details, the precise nature of clinical milestones, regulatory interactions, or strategic partnerships remains unclear from the financial data alone. However, the consistent investment levels and maintained cash reserves suggest the company continues executing on its established gene therapy development strategy across its rare disease portfolio, with management maintaining confidence in the clinical programs' advancement potential.
RCKT company profile · for informational purposes only — not investment advice.
Track RCKT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free